mounjaro and retatrutide vs Mounjaro: triple agonist versus dual agonist compared I'm getting asked about Retatrutide

The Lancet Diabetes and Endocrinology, 8, 524534

Underlying medical risks: Certain health conditions, medications, or personal medical histories can make GLP-1 therapy unsafe

Enrollees with obesity and overweight diagnoses have higher health spending than those without such diagnoses In 2021, people with large employer private insurance coverage who had an obesity or overweight diagnosis had an average of $12,588 in total annual health costs, which is more than double the $4,699 in health spending for those with no obesity or overweight diagnosis on their health insurance claims for that year

Find articles by Vulesevic, B

[DOI] [PubMed] [Google Scholar] [72].Pacheco-Pantoja EL, Ranganath LR, Gallagher JA, Wilson PJ, Fraser WD (2011)

Hydration strategies are critical, particularly for patients experiencing vomiting or diarrhea